Animal experiments show that the mosaic-type immunogen integrating key mutations from Omicron and other circulating variants elicits broad neutralization against divergent SARS-CoV-2 strains.

Selection acting on SARS-CoV-2 variants altering the infectivity profile depends on levels of transmission in the community, and this dependence is used to infer Alpha and Delta variants infectivity profiles.

Viral evolution can lead to mutations that render specific glycosylation sites dispensable for folding and for supporting the protein's function, allowing changes in the shield, and in the immunogenic profile.

A newly developed lateral flow assay can diagnose mutational signatures of major SARS CoV-2 variants in a rapid, inexpensive, and sequence-free manner.

COVID-19 mRNA vaccine-elicited T cells recognize variants of concern and phenotypically differ depending on number of vaccine doses and prior SARS-CoV-2 infection status.

Structural mass spectrometry reveals conformational changes in emerging SARS-CoV-2 spike protein variants that correlate with increased viral fitness.

SARS-CoV-2 spike variants that resist neutralization by therapeutic antibodies or convalescent plasma can be generated in the laboratory and exist at low frequency in natural populations.

HIV infection increases SARS-CoV-2 disease severity and alters immune cell dynamics in a beta variant dominated infection wave.

Single-molecule analysis of SARS-CoV-2 RNA identifies significant heterogeneity in cellular viral RNA levels and highlights slower replication kinetics for the Alpha variant compared to the Victoria strain.

Common variants of the SARS-CoV-2 Spike protein and its ligand, the human ACE2 receptor, increase the binding affinity, suggesting that they could increase viral transmissibility.